‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder

Vaderis Therapeutics has secured an oversubscribed $152 million series B financing to propel the Swiss biotech's AKT inhibitor through phase 3 with the aim of bringing the first treatment for a rare blood vessel disorder to market.